Cisco’s Insieme Ambitions, Catalyst Pharma’s Phase III Trials, and 3 More Hot Stocks
Cisco (NASDAQ:CSCO): Cisco has provided a few details on its Insieme unit, after its Catalyst switch refresh. Insieme is aiming to enable a data center infrastructure in which switches automatically adapt to the needs of apps, support developer APIs, and be able to use both custom ASICs and off-the-shelf processors, although Insieme adds that its ASICs support extra features. Cisco is also updating its Nexus data center switch line, so that it will support up to 192 100G ports and improved hardware automation.
Catalyst Pharmaceutical Partners (NASDAQ:CPRX): The company maintains that it expects to complete the enrollment of 36 patients in the Phase III trial of the Firdapse drug for Lambert-Eaton Myasthenic Syndrome, a rare and sometimes fatal autoimmune disease involving muscle weakness, during the fourth quarter of this year. Catalyst plans to file an NDA for Firdapse in the first quarter of 2015, get it authorized by the FDA at the end of the same year, and launch the treatment in the first half of 2016.
Citigroup (NYSE:C): Citigroup is spearheading efforts to disrupt the exclusive club of banks that has long dominated commodities trading, as larger banks who were forced to cut back face a renewed challenge from banks like Citi, which are building up their commodities trading teams to be ready for when the economy picks back up.
Lufkin Industries, Inc. (NASDAQ:LUFK): A special panel has cleared Lufkin of accusations that it breached its fiduciary duties in the way it handled General Electric’s (NYSE:GE) $2.98 billion acquisition of the oil pump manufacturer, following GE’s antitrust approval to purchase the company.